Development and in vitro evaluation of a drug delivery system protecting from trypsinic degradation

International Journal of Pharmaceutics

Volumn 157, Issue 1, 1997, Pages 17-25

  Bernkop Schnurch A ^a   Bratengeyer, I ^a   Valenta, C ^a  

^a Inst of Pharmaceutical Technology   (Austria)

Author keywords

Antipain; Chitosan; Mucoadhesive polymer; Peroral administration of (poly)peptides; Trypsin

Indexed keywords

ANTIPAIN; CHITOSAN; INSULIN; POLYMER; POLYPEPTIDE; TRYPSIN;

ARTICLE; CHEMICAL MODIFICATION; CONTROLLED DRUG RELEASE; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG STABILITY; ENZYME ACTIVITY; ENZYME IMMUNOASSAY; PRIORITY JOURNAL; PROTEIN DEGRADATION;

EID: 0030813427     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-5173(97)00198-1     Document Type: Article

References (29)

1. Akiyama Y., Lueßen H.L., de Boer A.G., Verhoef J.C., Junginger H.E. Design of fast dissolving poly(acrylate) and controlled drug-releasing capsule formulations with trypsin inhibiting properties. Int. J. Pharm. 138:1996;13-23.
2. Artursson P., Lindmark T., Davis S.S., Illum L. Effect of chitosan on the permeability of monolayers of intestinal epithelial cells (Caco-2). Pharm. Res. 11:1994;1358-1361.
3. Bernkop-Schnürch A., Fragner R. Investigations of the diffusion behaviour of polypeptides in native intestinal mucus with regard to their peroral administration. Pharm. Sci. 2:1996;361-363.
4. Bernkop-Schnürch A., Dundalek K. Novel bioadhesive drug delivery system protecting (poly)peptides from gastric enzymatic degradation. Int. J. Pharm. 138:1996;75-83.
5. Bernkop-Schnürch, A., 1997. Strategien zur peroralen Applikation von Peptid- und Proteinwirkstoffen. Sci. Pharm. (in press).
6. Bernkop-Schnürch A., Göckel N.C. Novel drug delivery system protecting from luminal enzymatic degradation caused by α-chymotrypsin. Drug Dev. Ind. Pharm. 23:1997;1-8.
7. Bernkop-Schnürch A., Apprich I. Synthesis and evaluation of a modified mucoadhesive polymer protecting from α-chymotrypsinic degradation. Int. J. Pharm. 146:1997;247-254.
8. Bernkop-Schnürch A., Marschütz M. Development and in vitro evaluation of systems to protect peptide drugs from aminopeptidase N. Pharm. Res. 14:1997;181-185.
9. Bernkop-Schnürch A., Schwarz G.H., Kratzel M. Modified mucoadhesive polymers for the peroral administration of mainly elastase degradable therapeutic (poly)peptides. J. Control. Release. 47:1997;113-121.
10. Bernkop-Schnürch A., Paikl C., Valenta C. Novel bioadhesive chitosan-EDTA conjugate protects leucine enkephalin from degradation by aminopeptidase N. Pharm. Res. 14:1997;917-922.
11. Davis S.S., Hardy J.G., Fara J.W. The transit of pharmaceutical dosage forms through the small intestine. Gut. 27:1986;886-892.
12. Drapeau G., Petitclerc E., Toulouse A., Marceau F. Dissociation of the antimicrobial activity of bacitracin USP from its renovascular effects. Antimicrob. Agents Chemother. 36:1992;955-961.
13. Fujii S., Yokoyama T., Ikegaya K., Sato F., Yokoo N. Promoting effect of the new chymotrypsin inhibitor FK-448 on the intestinal absorption of insulin in rats and dogs. J. Pharm. Pharmacol. 37:1985;545-549.
14. Ikesue K., Kopeckova P., Kopecek J. Degradation of proteins by guinea pig intestinal enzymes. Int. J. Pharm. 95:1993;171-179.
15. Illum L., Farraj N.F., Davis S.S. Chitosan as a novel nasal delivery system for peptide drugs. Pharm. Res. 11:1994;1186-1189.
16. Junginger H.E. Bioadhesive polymer systems for peptide delivery. Acta Pharm. Technol. 36:1990;110-126.
17. Lehr C.-M., Bouwstra J.A., Schacht E.H., Junginger H.E. In vitro evaluation of mucoadhesive properties of chitosan and some other natural polymers. Int. J. Pharm. 78:1992;43-48.
18. Lehr C.-M. Bioadhesion technologies for the delivery of peptide and protein drugs to the gastrointestinal tract. Crit. Rev. Ther. Drug. 11:1994;119-160.
19. Lueßen H.L., Verhoef J.C., Borchard G., Lehr C.-M., de Boer A.G., Junginger H.E. Mucoadhesive polymers in the peroral peptide drug delivery. II. Carbomer and polycarbophil are potent inhibitors of the intestinal proteolytic enzyme trypsin. Pharm. Res. 12:1995;1293-1298.
20. Lueßen H.L., de Leeuw B.J., Pérard D., Lehr C.-M., de Boer A.G., Verhoef J.C., Junginger E.H. Mucoadhesive polymers in peroral peptide drug delivery. I. Influence of mucoadhesive excipients on the proteolytic activity of intestinal enzymes. Eur. J. Pharm. Sci. 4:1996;117-128.
21. Morishita I., Morishita M., Takayama K., Machida Y., Nagai T. Hypoglycemic effect of novel oral microspheres of insulin with protease inhibitor in normal and diabetic rats. Int. J. Pharm. 78:1992;9-16.
22. Nitsan Z., Nir I. Accentuated response to soybean inhibitors by meal-feeding in various species. Adv. Exp. Med. Biol. 199:1986;199-222.
23. Rick W. Der Secretin-Pankreozymin-Test in der Diagnostik der Pankreasinsuffizienz. Internist. 11:1970;110-117.
24. Schilling R.J., Mitra A.K. Degradation of insulin by trypsin and α-chymotrypsin. Pharm. Res. 8:1991;721-727.
25. Watanabe S., Takeuchi T., Chey W.Y. Mediation of trypsin inhibitor-induced pancreatic hypersecretion by secretin and cholecystokinin in rats. Gastroenterology. 102:1992;621-628.
26. Wissenschaftliche Tabellen Geigy, 1983. Ciba-Geigy, Basel, 8th ed, 1983.
27. Woodley J.F. Enzymatic barriers for GI peptide and protein delivery. Crit. Rev. Ther. Drug. 11:1994;61-95.
28. Yagi T., Ishizaki K., Takebe H. Cytotoxic effects of protease inhibitors on human cells. II. Effect of elastatinal. Cancer Lett. 10:1980;301-307.
29. Zhou X.H. Overcoming enzymatic and absorption barriers to non-parenterally administer protein and peptide drugs. J. Control. Release. 29:1994;239-252.